Publications by authors named "Jacob Haling"

Claim this Profile
T
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, Lars D Engstrom, Jade Laguer, Jacob Haling

Mol Cancer Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor efficacy of a potent and selective non-covalent KRAS inhibitor.
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M Briere, Lauren Hargis, Jacob R Haling

Nat Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
John M Ketcham, Jacob Haling, Shilpi Khare, Vickie Bowcut, David M Briere

J Med Chem· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EndoBind detects endogenous protein-protein interactions in real time.
Anke Bill, Sheryll Espinola, Daniel Guthy, Jacob R Haling, Mylene Lanter

Commun Biol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design of Selective LONP1 Inhibitors for Probing Biology.
Laura J Kingsley, Xiaohui He, Matthew McNeill, John Nelson, Victor Nikulin, Jacob R Haling

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Discovery of -(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.
Savithri Ramurthy, Benjamin R Taft, Robert J Aversa, Paul A Barsanti, Matthew T Burger, Jacob R Haling

J Med Chem· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Wenlin Shao, Yuji M Mishina, Yun Feng, Giordano Caponigro, Vesselina G Cooke, Jacob R Haling

Cancer Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Caroline M Emery, Kelli-Ann Monaco, Ping Wang, Marissa Balak, Alyson Freeman, Jacob Haling

Mol Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
Gisele A Nishiguchi, Alice Rico, Huw Tanner, Robert J Aversa, Benjamin R Taft, Jacob R Haling

J Med Chem· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
Jacob R Haling, Jawahar Sudhamsu, Ivana Yen, Steve Sideris, Wendy Sandoval

Cancer Cell· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
Georgia Hatzivassiliou, Jacob R Haling, Huifen Chen, Kyung Song, Steve Price

Nature· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talin-dependent integrin activation is required for fibrin clot retraction by platelets.
Jacob R Haling, Susan J Monkley, David R Critchley, Brian G Petrich

Blood· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abl-interactor-1 (Abi1) has a role in cardiovascular and placental development and is a binding partner of the alpha4 integrin.
Colleen Ring, Mark H Ginsberg, Jacob Haling, Ann Marie Pendergast

Proc Natl Acad Sci U S A· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) reprograms growth factor signaling by inhibiting threonine phosphorylation of fibroblast receptor substrate 2alpha.
Jacob R Haling, Fen Wang, Mark H Ginsberg

Mol Biol Cell· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beta integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation.
Nicholas J Anthis, Jacob R Haling, Camilla L Oxley, Massimiliano Memo, Kate L Wegener

J Biol Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An experimentally derived database of candidate Ras-interacting proteins.
Lawrence E Goldfinger, Celeste Ptak, Erin D Jeffery, Jeffrey Shabanowitz, Jaewon Han, Jacob R Haling

J Proteome Res· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis